v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
We manage our operations as a single reportable and operating segment for the purposes of assessing performance and making operating decisions. Our chief operating decision maker (“CODM”) is made up of our Chief Executive Officer and Chief Financial Officer. The CODM assesses performance and manages and allocates resources on a total company basis. Further, the CODM reviews and utilizes functional expenses at the consolidated level to manage our operations. The measure of segment assets is reported on the consolidated balance sheets as total assets.
The following table provides information about our single segment:

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Operating Expenses:
Significant components of research and development (R&D) expenses:
Clinical trial expenses$1,056 $422 $1,803 $792 
Manufacturing and related process development expenses413 425 920 839 
Personnel-related expenses2,699 1,045 5,970 3,026 
Significant components of general and administrative (G&A) expenses:
Public company-related expenses3,368 1,580 6,384 2,780 
Personnel-related expenses1,371 888 2,601 1,625 
Intellectual property expenses149 85 451 192 
All other R&D and G&A expenses323 206 531 418 
Total operating expenses9,379 4,651 18,660 9,672 
Loss from operations(9,379)(4,651)(18,660)(9,672)
Total other income (expense), net38 (565)76 (255)
Income tax expense(101)(61)(101)(61)
Net loss$(9,442)$(5,277)$(18,685)$(9,988)